Upgrade to SI Premium - Free Trial

Teladoc (TDOC) Tops Q4 EPS by 7c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus

February 26, 2020 4:05 PM

Teladoc (NYSE: TDOC) reported Q4 EPS of ($0.26), $0.07 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $156.49 million versus the consensus estimate of $152.95 million.

“We demonstrated outstanding performance in the fourth quarter and full year of 2019 as we reported record results that were at the high end or exceeded our expectations on all key metrics. Our diversified growth strategies are driving strong growth across our channels,” said Jason Gorevic, chief executive officer. “Looking forward, we are well positioned with significant momentum to extend our leadership position and to meet the increasing demand for our comprehensive service offering.”

GUIDANCE:

Teladoc sees Q1 2020 EPS of ($0.37)-($0.34), versus the consensus of ($0.36). Teladoc sees Q1 2020 revenue of $169-172 million, versus the consensus of $163.88 million.

Teladoc sees FY2020 EPS of ($1.19)-($1.06), versus the consensus of ($1.19). Teladoc sees FY2020 revenue of $695-710 million, versus the consensus of $692.86 million.

Teladoc Health provides guidance based on current market conditions and expectations.

For the first-quarter 2020, we expect:

For the full-year 2020, we expect:

For earnings history and earnings-related data on Teladoc (TDOC) click here.

Categories

Corporate News Earnings Guidance Hot Guidance Management Comments

Next Articles